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Carbohydrate-binding agents (CBA) represent a broad
family of agents that recognize specific glycan conforma-
tions. Several members of this compound family includ-
ing peptidicprokaryotic, plant, invertebrate and
vertebrate lectins, but also the well-defined non-pepti-
dicpradimicin and benanomicin antibiotics have shown
to be endowed with anti-HIV activity. These compounds
inhibit entry of virus particles in susceptible T-lympho-
cytes and macrophages, block syncytia formation
between HIV-infected and non-infected T-lymphocytes,
prevent capture of HIV by DC-SIGN-expressing cells
and by the macrophage mannose receptor and prevent
subsequent transmission of captured HIV to susceptible
T-lymphocytes. No other antiviral class of compounds
have been demonstrated to block these four important
ways of HIV infection/transmission, which make the
CBAs an interesting new family of potential anti-HIV
drugs that may be particularly useful for both systemic
and topical (i.e. microbicidal) applications. CBAs bind to
the glycans of the HIV envelope gpl 20 and block viral
entry, most likely by freezing the envelope conformation
during viral entry. Escalating drug pressure in HIV-
infected cell cultures result in the selection of mutant
virus strains predominantly having one or several N-gly-
can deletions in their envelope gp120.ln this respect,
many CBAs have a high genetic barrier since several N-
glycan deletions seem to be required for significant phe-
notypic drug resistance. Interestingly, mutant virus
strains containing an increasing amount of N-glycan
deletions in gp120 tend to show a compromised ínfec-
tivity potential. Moreover, we have found one specific,
highly conserved N-glycan in HIV-1 gp120, whose dele-
tion results in the production of noninfectious virus par-
ticles lacking gp41gp120 in their envelope. This N-
glycan may be regarded as a hot-spot for a targeted
therapeutic intervention. Also, it is expected that if
mutant virus particles lacking N-glycans in gp120 are
selected under CBA pressure in vivo, as shown to occur
in drug-exposed HIV-and SIV-infected cell cultures,
previously hidden conserved immunogenic epitopes
become exposed, allowing the immune system to speci-
fically trigger an efficient immune response against
these viruses. An in vivo study using SIV-infected mon-
keys has been planned to explore this new therapeutic
concept.
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